New FDA approved antibacterial drugs: 2015-2017.
New FDA approved antibacterial drugs: 2015-2017.
复制标题
DOI：
10.15190/d.2018.1
复制
发表时间：
2018-04-04
期刊：
影响因子：
--
通讯作者：
Stefan, Mihai-Gabriel
中科院分区：
文献类型：
--
作者：
Andrei, Stefan;Valeanu, Liana;Stefan, Mihai-Gabriel
细菌对抗生素的耐药性增加是一个世界范围内持续存在的问题。对新型抗菌剂的迫切需求导致了重大的研究工作，并提出了用于临床实践的新分子。然而，正如许多团体所强调的那样，这一过程并不具有最佳的节奏和功效，无法充分对抗高度适应性的细菌，特别是在重症监护病房中。本综述重点关注过去三年 FDA 批准的新型抗菌药物（2015-2017 年）：头孢他啶/阿维巴坦、奥比沙昔单抗、贝洛妥单抗、德拉沙星、美罗培南/伐硼巴坦、奥泽沙星。头孢他啶/阿维巴坦和美罗培南/伐硼巴坦是耐药菌治疗领域的新参与者。头孢他啶/阿维巴坦在选定的患有复杂性尿路或腹腔内感染、医院和呼吸机相关性肺炎的患者中得到验证。美罗培南/伐硼巴坦获得批准用于治疗复杂的尿路感染病例。其他潜在的适应症正在调查中，并通过未来的研究进行扩大和验证。 Obiltoxaximab 是一种单克隆抗体，可用于预防和治疗吸入性炭疽。 Bezlotoxumab 单克隆抗体是治疗复发性艰难梭菌感染的有用且特异的工具。德拉沙星被批准用于患有急性皮肤或皮肤结构感染的患者。尽管最近取得了进展，但仍必须继续开发新的抗生素药物和新策略来对抗抗生素耐药性。
Increasing bacterial resistance to antibiotics is a worldwide ongoing issue. Urgent need for new antibacterial agents has resulted in significant research efforts, with new molecules proposed for use in clinical practice. However, as highlighted by many groups this process does not have an optimal rhythm and efficacy, to fully combat highly adaptive germs, particularly in the intensive care units. This review focuses on the last three years of novel FDA approved antibacterial agents (2015-2017): ceftazidime/avibactam, obiltoxaximab, bezlotoxu-mab, delafloxacin, meropenem/vaborbactam, ozenoxacin. Ceftazidime/avibactam and meropenem/ vaborbactam are new players in the field of resistant bacteria treatment. Ceftazidime/avibactam is validated in selected patients with complicated urinary or intra-abdominal infections, hospital and ventilator-associated pneumonia. Meropenem/ vaborbactam gained approval for the cases of complicated urinary tract infections. Other potential indications are under investigation, widened and validated by future studies. Obiltoxaximab is a monoclonal antibody that can be used in the prevention and treatment of inhalational anthrax. Bezlotoxumab monoclonal antibody is an useful and specific tool for the management of recurrent Clostridium difficile infection. Delafloxacin is approved for patients with acute skin or skin structure infections. Despite recent progress, it is imperative to continue the development of new antibiotic drugs and new strategies to counteract resistance to antibiotics.